A new study in the British Journal of Cancer reports an organoid system designed to recapitulate basal-classical diversity in pancreatic cancer using a dual-oxygen approach. The work uses organoid modeling and spatial transcriptomics to show that a single tumor can display multiple disease-like states, and it builds an in vitro platform aimed at mirroring that heterogeneity. For translational teams, the advance offers a more controlled experimental setting for testing therapies against distinct tumor states that may vary in hypoxia sensitivity and gene expression programs. It also strengthens the case for spatially grounded evaluation of treatment effects beyond bulk profiling.